Shore Capital Reaffirms Hold Rating for AstraZeneca (AZN)

Share on StockTwits

AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by research analysts at Shore Capital in a research report issued to clients and investors on Tuesday.

AZN has been the subject of a number of other reports. UBS Group reiterated a “neutral” rating and issued a GBX 5,600 ($73.17) target price on shares of AstraZeneca in a research note on Monday, July 2nd. Deutsche Bank lowered their target price on shares of AstraZeneca from GBX 6,000 ($78.40) to GBX 5,700 ($74.48) and set a “buy” rating for the company in a research note on Friday, July 20th. BNP Paribas set a GBX 6,500 ($84.93) price target on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Tuesday, September 11th. JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price target on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Tuesday, September 25th. Finally, Barclays set a GBX 6,500 ($84.93) price target on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Friday, July 27th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of GBX 5,705.70 ($74.56).

AZN stock opened at GBX 5,856 ($76.52) on Tuesday. AstraZeneca has a 52 week low of GBX 4,260 ($55.66) and a 52 week high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: Dividend

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply